Gerald Schmid‐Bindert

Author

Heidelberg University

Also Known As

G Schmid-Bindert, G. Schmid-Bindert, GERALD SCHMID‐BINDERT, Gerald Schmid-Bindert, Gerald Schmid‐Bindert

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Heidelberg University University Hospital Heidelberg University Medical Centre Mannheim Shanghai Pulmonary Hospital Tongji University

About

Gerald Schmid‐Bindert is an author at Heidelberg University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	22	1.2K
2	Health Sciences	7	7	284
3	Cell Biology	3	3	155
4	Engineering	1	1	122
5	Biomedical Engineering	1	1	17

Gerald Schmid‐Bindert

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Oliver Gautschi, Julie Milia, Bastien Cabarrou, Journal of Thoracic Oncology MedicinePathologyEuropean Euraf CohortImmune Checkpoint InhibitorBronchial Neoplasm	2015	186
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules Chunyan Wu, Chao Zhao, Yang Yang, Journal of Thoracic Oncology Somatic VariantDriver MutationsAdvanced Lung DiseaseMultiple Pulmonary NodulePathology	2015	142
Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Gerald Schmid‐Bindert, Thomas Henzler, T. Q. Chu, European Radiology Positron Emission TomographyEngineeringOncologic ImagingMedical ImagingPet-mri	2011	122
MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines Yongsheng Wang, Yinhua Wang, Hongping Xia, Asian Pacific Journal of Cancer Prevention	2012	114
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians Yongsheng Wang, Gerald Schmid‐Bindert, Caicun Zhou Therapeutic Advances in Medical Oncology Tumor BiologyAdvanced NsclcMedicinePharmacologyMetastatic Nsclc	2011	111
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) Suresh S. Ramalingam, Glenwood Goss, Rafael Rosell, Annals of Oncology OncologyHeat ShockMedicinePathologyImmune Checkpoint Inhibitor	2015	106
ROS1 fusions in Chinese patients with non-small-cell lung cancer W. Cai, X. Li, Chunxia Su, Annals of Oncology OncologyMedicinePathologyCancer GeneticsCancer Biology	2013	89
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients Wěi Li, Shengxiang Ren, Jiayu Li, Lung Cancer Clinical TranslationMedicineBetter EfficacyPathologyAdvanced Nsclc Patients	2014	88
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines H Li, Gerald Schmid‐Bindert, D Wang, Advances in Medical Sciences MedicineReceptor Tyrosine KinaseCancer BiologyCell BiologyOncology	2011	85
Predicting malignancy in mediastinal lymph nodes by endobronchial ultrasound: A new ultrasound scoring system Gerald Schmid‐Bindert, Hongbin Jiang, Georg Kähler, Respirology	2012	65

Page 1